Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab

IF 2.9 4区医学 Q2 CLINICAL NEUROLOGY Neurologia Pub Date : 2023-09-01 DOI:10.1016/j.nrl.2021.01.010

E.M. Alba Suárez , A. Tallón Barranco , I. Puertas Muñoz , B. Chamorro Hernández , Á. Robles Marhuenda

{"title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","authors":"E.M. Alba Suárez , A. Tallón Barranco , I. Puertas Muñoz , B. Chamorro Hernández , Á. Robles Marhuenda","doi":"10.1016/j.nrl.2021.01.010","DOIUrl":null,"url":null,"abstract":"<div>Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5×103     <!-->28 days.Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis.We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.</div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"38 7","pages":"Pages 463-466"},"PeriodicalIF":2.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.nrl.2021.01.010","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213485321000268","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5 × 10³ cells/μL starting > 4 weeks after the last dose of rituximab, in the absence of other identifiable causes.

Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of > 28 days.

Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis.

We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

ocrelizumab治疗多发性硬化症后非迟发性中性粒细胞增多症

晚发性中性粒细胞增多症定义为<；×103个细胞/μ；在没有其他可识别原因的情况下，在最后一剂利妥昔单抗后4周。迟发性中性粒细胞增多症是一种罕见的利妥昔单抗不良反应（约5%的患者出现）。风湿性疾病是利妥昔单抗的主要适应症；在这些患者中，中性粒细胞增多症在平均>；28天。Ocrelizumab是另一种与CD20（一种主要在B淋巴细胞膜上表达的糖基化磷蛋白）结合的单克隆抗体；2018年1月，它被批准用于治疗复发缓解型和原发性进行性多发性硬化症。我们报告了一例静脉输注ocrelizumab后出现中性粒细胞增多症的原发性进行性多发性硬化症患者，该患者在输注后仅20天就出现了中性粒细胞热、疱疹性口炎和坏疽性脓疮。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neurologia 医学-临床神经学

CiteScore

5.90

自引率

2.60%

发文量

135

审稿时长

48 days

期刊介绍： Neurología es la revista oficial de la Sociedad Española de Neurología y publica, desde 1986 contribuciones científicas en el campo de la neurología clínica y experimental. Los contenidos de Neurología abarcan desde la neuroepidemiología, la clínica neurológica, la gestión y asistencia neurológica y la terapéutica, a la investigación básica en neurociencias aplicada a la neurología. Las áreas temáticas de la revistas incluyen la neurologia infantil, la neuropsicología, la neurorehabilitación y la neurogeriatría. Los artículos publicados en Neurología siguen un proceso de revisión por doble ciego a fin de que los trabajos sean seleccionados atendiendo a su calidad, originalidad e interés y así estén sometidos a un proceso de mejora. El formato de artículos incluye Editoriales, Originales, Revisiones y Cartas al Editor, Neurología es el vehículo de información científica de reconocida calidad en profesionales interesados en la neurología que utilizan el español, como demuestra su inclusión en los más prestigiosos y selectivos índices bibliográficos del mundo.